ARTICLE | Company News
Oscient gains worldwide ramoplanin rights
February 9, 2006 3:10 AM UTC
OSCI acquired expanded rights to ramoplanin from Pfizer (PFE) subsidiary Vicuron. OSCI, which already had North American rights, now has worldwide rights to the macrocyclic depsipeptide inhibitor of p...